Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Seasonal Allergic Rhinitis
Conditions
Seasonal Allergic Rhinitis
Trial Timeline
Jan 27, 2014 → Feb 28, 2014
NCT ID
NCT03444506About Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray is a phase 2 stage product being developed by Glenmark Pharmaceuticals for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03444506. Target conditions include Seasonal Allergic Rhinitis.
What happened to similar drugs?
20 of 20 similar drugs in Seasonal Allergic Rhinitis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03444506 | Phase 2 | Completed |
Competing Products
20 competing products in Seasonal Allergic Rhinitis